We are holding steady to our fair value estimate and wide moat rating for Pfizer PFE following first-quarter results that largely matched our expectations. The company is tracking well to meet its ...

Despite Wall Street's continued conservatism regarding its business prospects, Pfizer beat analysts' expectations for the second quarter of 2024. In addition to the raised full-year 2024 guidance, the ...

The pharmaceutical giant reaffirmed the modest 2026 outlook that rattled investors in December.

Pfizer reported positive Phase 2b results for its monthly GLP-1 obesity drug candidate PF-3944, with plans to run more than ...

Activist investor Starboard Value has amassed a $1 billion stake in Pfizer, according to a report, with a turnaround in its sights. The pharmaceutical company has been struggling postpandemic to ...